Cargando…
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic the...
Autores principales: | Kim, Hye-Jin, Koo, So-My, Ham, Nam-Suk, Kim, Ki-Up, Uh, Soo-taek, Kim, Yang-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982239/ https://www.ncbi.nlm.nih.gov/pubmed/24734100 http://dx.doi.org/10.4046/trd.2014.76.3.127 |
Ejemplares similares
-
Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report
por: Koo, So-My, et al.
Publicado: (2021) -
p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up
por: Koo, So-My, et al.
Publicado: (2014) -
Clinical Experiences of High-Risk Pulmonary Thromboembolism Receiving Extracorporeal Membrane Oxygenation in Single Institution
por: Jang, Joonyong, et al.
Publicado: (2022) -
Incidence and Risk Factors of Pneumonia in Hospitalized Patients with Seasonal Influenza A or B
por: Chu, Seongjun, et al.
Publicado: (2017) -
Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism
por: Yan, Denise Tan, et al.
Publicado: (2019)